Zeo ScientifiX, Inc. Files 8-K for Agreements and Officer Changes
Ticker: ZEOX · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1557376
Sentiment: neutral
Topics: material-agreement, officer-changes, director-changes, exhibits
TL;DR
Zeo ScientifiX (ZEO) filed an 8-K for new deals and exec changes - watch for updates.
AI Summary
On February 4, 2025, Zeo ScientifiX, Inc. reported a material definitive agreement and changes in its officer and director positions. The company also filed financial statements and exhibits related to these events. Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc. and has undergone several name changes.
Why It Matters
This filing indicates significant corporate actions, including new agreements and potential leadership shifts, which could impact the company's strategic direction and operational focus.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in officers/directors, which can introduce uncertainty and potential strategic shifts.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- Organicell Regenerative Medicine, Inc. (company) — Former company name
- February 4, 2025 (date) — Date of earliest event reported
- February 10, 2025 (date) — Filing date
FAQ
What is the nature of the material definitive agreement filed by Zeo ScientifiX, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.
What specific changes occurred regarding directors or officers on February 4, 2025?
The filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements, but specific names are not detailed in the provided summary.
When was Zeo ScientifiX, Inc. previously known by another name?
Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc., with a name change date of June 25, 2018.
What is the SIC code for Zeo ScientifiX, Inc.?
The Standard Industrial Classification (SIC) code for Zeo ScientifiX, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the business address and phone number for Zeo ScientifiX, Inc.?
The business address is 3321 College Avenue, Suite 246, Davie, FL 33314, and the business phone number is 888-963-7881.
Filing Stats: 1,702 words · 7 min read · ~6 pages · Grade level 12.6 · Accepted 2025-02-10 08:35:24
Key Financial Figures
- $220,000 — agreement provides for a base salary of $220,000 for the first year and $235,000 per ann
- $235,000 — lary of $220,000 for the first year and $235,000 per annum for each subsequent year it i
- $15,000 — effect, subject to adjustment of up to $15,000, in the event certain compensation unde
- $3.05 — hares of our common stock at a price of $3.05 per share (fair market value on the dat
Filing Documents
- zeoscientifix_8k.htm (8-K) — 53KB
- zeoscientifix_ex10-1.htm (EX-10.1) — 68KB
- 0001829126-25-000818.txt ( ) — 306KB
- ocel-20250204.xsd (EX-101.SCH) — 3KB
- ocel-20250204_lab.xml (EX-101.LAB) — 33KB
- ocel-20250204_pre.xml (EX-101.PRE) — 22KB
- zeoscientifix_8k_htm.xml (XML) — 3KB
01
Item 1.01 Entry into a Material Definitive Agreement. On February 4, 2025, the Company entered into a Binding Memorandum of Understanding (the " Binding MOU ") with BioXtek, LLC, a Florida limited liability company (" BioXtek ") setting forth the terms of a joint development, manufacturing, marketing and funding arrangement to be entered into by the Company and BioXtek in various phases (the " Joint Venture "). BioXtek is a privately-held Florida-based company engaged in the development, manufacturing and marketing of biologic regenerative therapeutics, with a focus on human placental tissue-derived (" HAF ") products. BioXtek manufactures products both for itself and third parties. BioXtek's primary revenues are derived from the sale of membrane patches that are used primarily in the wound care and surgical markets (" Membrane Products "). BioXtek operates a cGMP, cGTP and AATB compliant 11,000 square foot manufacturing facility in Pompano Beach, Florida (the " BioXtek Facility "). The Joint Venture contemplates, among other matters: ZEO relocating its current operations located at Nova Southeastern University in Davie, Florida, to sublet space at the BioXtek Facility in Pompano Beach, Florida expected to be completed by May 31. 2025, which will include administrative, laboratory (research and development) and clean room (tissue processing) space, as well as shared common area space; BioXtek providing ZEO with the services of BioXtek technical, quality control and shipping personnel, as well as additional use of clean rooms, as ZEO may reasonably request, at agreed upon rates; If requested by ZEO and subject to BioXtek meeting ZEO's quality control and regulatory compliance, BioXtek becoming the exclusive contract manufacturer for ZEO's HAF and peripheral blood derived products; ZEO and BioXtek establishing a jointly-owned (50/50) special purpose entity (the " SPE "), to pursue the development and commercialization of agreed upon products including
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (" Dr. Everts" ) was appointed the Company's Chief Scientific and Technology Officer. Dr. Everts, 63, has spent his professional career dedicated to regenerative and Ortho biological applications and technologies, both as a clinician and as a health care executive. Prior to joining ZEO, he served as Chief Scientific Officer at EmCyte Corporation and as Educational Program Director at Gulf Coast Biologics from July 2017 to December 2024. In this capacity, he participated in many research programs and was involved in the development of advanced autologous biological protocols for treatment of musculoskeletal and spine disorders, as well as aesthetic procedures. In those efforts, Dr. Evert collaborated with various U.S. and foreign universities, and focused on bioformulations designed to improve patient outcomes. In 2010 Dr. Everts co-founded the Da Vinci Clinic in the Netherlands and served as Chairman of its Board of Directors from 2010 to 2017. The clinic specialized in hyperbaric medicine combined with advanced biological therapies for patients with complex chronic, radiation, and traumatic wounds. Prior thereto, he served as Chief Scientific and Technology Officer for Avance Medical, Switzerland from 2011 to 2016, where he directed regenerative medicine and cell therapies for distribution to European and Middle East markets. Dr. Everts received his Ph.D. in medicine from the University of Utrecht, the Netherlands in 2007. Dr. Everts currently holds an adjunct professorship at the University of Queensland in Brisbane Australia and is an International Professor at the Max Planck University in Indaiatuba-SP Brazil. The Company has entered into an employment agreement with Dr. Everts effective February 7, 2025. Dr. Everts' employment agreement provide
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 10, 2025 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell Interim Chief Executive Officer and Chief Financial Officer 4